TAR RNA
Nuclear Factor 90(NF90) targeted to TAR RNA inhibits transcriptional activation of HIV 1
10
The Human Immunodeficiency Virus Type 1 TAR RNA Upper Stem-Loop Plays Distinct Roles in Reverse Transcription and RNA Packaging
8
Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription
13
Specific repression of Tax trans-activation by TAR RNA-binding protein TRBP.
8
Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein
11
A proteomic study of TAR-RNA binding protein (TRBP)-associated factors
5
The Cellular TAR RNA Binding Protein, TRBP, Promotes HIV-1 Replication Primarily by Inhibiting the Activation of Double-Stranded RNA-Dependent Kinase PKR
8
Small Interfering RNAs against the TAR RNA Binding Protein, TRBP, a Dicer Cofactor, Inhibit Human Immunodeficiency Virus Type 1 Long Terminal Repeat Expression and Viral Production
11
Role of TAR RNA splicing in translational regulation of simian immunodeficiency virus from rhesus macaques.
10
TAR RNA binding properties and relative transactivation activities of human immunodeficiency virus type 1 and 2 Tat proteins.
12
Conserved nucleotides in the TAR RNA stem of human immunodeficiency virus type 1 are critical for Tat binding and trans activation: model for TAR RNA tertiary structure.
8
Human immunodeficiency virus type 1 TAR element revertant viruses define RNA structures required for efficient viral gene expression and replication.
8
A dual function TAR Decoy serves as an anti HIV siRNA delivery vehicle
9
ADAR1 Interacts with PKR during Human Immunodeficiency Virus Infection of Lymphocytes and Contributes to Viral Replication
10
The role of exosomal transport of viral agents in persistent HIV pathogenesis
13
Juxtaposition between activation and basic domains of human immunodeficiency virus type 1 Tat is required for optimal interactions between Tat and TAR.
5
Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.
9
A Randomised Controlled Trial of the Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy) Compared with 0.25% Desoximetasone Cream (Topicorte) for the Treatment of Scalp Psoriasis
9
Rna Interference: Progress In Delivery Strategies And Therapeutic Application
7
Targeting Tat Inhibitors in the Assembly of Human Immunodeficiency Virus Type 1 Transcription Complexes
13